4J3N
 
 | | Human Topoisomerase Iibeta in complex with DNA | | Descriptor: | DNA (5'-D(P*AP*GP*CP*CP*GP*AP*GP*C)-3'), DNA (5'-D(P*TP*GP*CP*AP*GP*CP*TP*CP*GP*GP*CP*T)-3'), DNA topoisomerase 2-beta, ... | | Authors: | Wu, C.C, Li, T.K, Li, Y.C, Chan, N.L. | | Deposit date: | 2013-02-06 | | Release date: | 2013-10-02 | | Last modified: | 2023-11-08 | | Method: | X-RAY DIFFRACTION (2.3 Å) | | Cite: | On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs
Nucleic Acids Res., 41, 2013
|
|
4G0W
 | | Human topoisomerase iibeta in complex with DNA and ametantrone | | Descriptor: | 1,4-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione, DNA (5'-D(P*AP*GP*CP*CP*GP*AP*GP*C)-3'), DNA (5'-D(P*TP*GP*CP*AP*GP*CP*TP*CP*GP*GP*CP*T)-3'), ... | | Authors: | Wu, C.C, Li, T.K, Li, Y.C, Chan, N.L. | | Deposit date: | 2012-07-10 | | Release date: | 2013-07-17 | | Last modified: | 2024-10-16 | | Method: | X-RAY DIFFRACTION (2.696 Å) | | Cite: | On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs
Nucleic Acids Res., 41, 2013
|
|
4G0U
 | | Human topoisomerase IIbeta in complex with DNA and amsacrine | | Descriptor: | DNA (5'-D(P*AP*GP*CP*CP*GP*AP*GP*C)-3'), DNA (5'-D(P*TP*GP*CP*AP*GP*CP*TP*CP*GP*GP*CP*T)-3'), DNA topoisomerase 2-beta, ... | | Authors: | Wu, C.C, Li, T.K, Li, Y.C, Chan, N.L. | | Deposit date: | 2012-07-10 | | Release date: | 2013-07-17 | | Last modified: | 2024-10-09 | | Method: | X-RAY DIFFRACTION (2.7 Å) | | Cite: | On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs
Nucleic Acids Res., 41, 2013
|
|
4G0V
 | | Human topoisomerase iibeta in complex with DNA and mitoxantrone | | Descriptor: | 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE, DNA (5'-D(P*AP*GP*CP*CP*GP*AP*GP*C)-3'), DNA (5'-D(P*TP*GP*CP*AP*GP*CP*TP*CP*GP*GP*CP*T)-3'), ... | | Authors: | Wu, C.C, Li, T.K, Li, Y.C, Chan, N.L. | | Deposit date: | 2012-07-10 | | Release date: | 2013-07-17 | | Last modified: | 2024-10-30 | | Method: | X-RAY DIFFRACTION (2.548 Å) | | Cite: | On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs
Nucleic Acids Res., 41, 2013
|
|
